The startup develops non-invasive medical devices that utilize localized cooling technologies to deliver therapeutic treatments without skin penetration. This approach provides healthcare providers with a safe and effective method for managing pain and inflammation in patients.

Areteia Therapeutics is developing dexpramipexole, a first-in-class oral medication that inhibits eosinophil maturation to reduce inflammation in patients with eosinophilic asthma. This approach addresses the significant unmet need for effective treatments in a condition affecting millions globally, where current therapies often fall short.

The startup develops reformulated biopharmaceutical drugs that utilize new chemical entities to enhance the identification of biologics and small molecules. This approach streamlines regulatory strategies and clinical programs, enabling biotech companies to efficiently meet drug demands and improve patient outcomes.

Basking Biosciences is developing BB-031, a reversible RNA aptamer designed to target von Willebrand Factor for the treatment of acute ischemic stroke. This therapy aims to provide a rapid-onset, short-acting solution for reopening blocked arteries while allowing for quick neutralization in case of bleeding complications.

CryOSA is developing a medical device that employs targeted airway pressure modulation to treat obstructive sleep apnea. This non-invasive approach enhances patient compliance and minimizes the risk of health complications associated with traditional CPAP therapy.

Dimension Inx develops biomaterials that create regenerative microenvironments to enhance cell functionality and restore organ function. Their technology addresses the limitations of traditional cell therapies by providing a three-dimensional matrix that promotes vascular integration and durable therapeutic responses.

Elira develops a drug-free wearable device that utilizes biofeedback technology to help users monitor and manage their weight. This device addresses the challenge of weight control by providing real-time insights into physiological responses, enabling users to make informed lifestyle choices.

Francis Medical is developing the Vanquish® Water Vapor Ablation System, which utilizes thermal energy from sterile water vapor to ablate cancerous prostate tissue through a minimally invasive transurethral procedure. This technology aims to reduce the severe side effects associated with traditional prostate cancer treatments, allowing patients to return to their normal activities the day after the procedure.

InterShunt is developing a transcatheter system that excises tissue from the interatrial septum to create a left-to-right atrial shunt, effectively relieving elevated left atrial pressure in heart failure patients. This minimally invasive procedure aims to improve breathing and daily activity levels for over 6 million Americans suffering from heart failure.

I-O Urology offers CarePath®, a remote patient monitoring system specifically designed for urologic care at home, which collects reliable data every time a patient voids. This technology eliminates the need for handwritten voiding diaries and bulky commode hats, providing healthcare providers with accurate and comprehensive data for more confident diagnoses.

The startup operates a digital pathology platform that utilizes computational microscopy and artificial intelligence to analyze tissue samples with high speed and accuracy. This technology enables healthcare providers to achieve earlier and more precise diagnoses, ultimately improving patient outcomes and reducing the time required for diagnostic processes.

Phenomics Health is a bioinformatics platform that integrates genomic and phenotypic data to create personalized treatment plans for patients. The platform enhances therapeutic outcomes by providing insights tailored to individual biological profiles, addressing the inefficacy of standard treatment approaches.

The startup develops uterine electromyography monitoring sensors that measure independent contraction activity across different regions of the uterus during all stages of pregnancy. These sensors enhance the management of preterm labor and delivery processes, improving maternal and neonatal outcomes in hospital settings.

Rediscovery Life Sciences utilizes drug repurposing to develop biopharmaceuticals with reduced safety risks and improved efficacy profiles. This approach addresses the high failure rates and lengthy timelines associated with traditional drug development by leveraging existing medications for new therapeutic uses.

Stimdia Medical has developed the pdSTIM™ System, a neurostimulation therapy that uses percutaneously inserted leads to stimulate the phrenic nerves and recondition the diaphragm for independent breathing. This technology addresses ventilator-induced diaphragmatic dysfunction in mechanically ventilated adults, facilitating faster weaning from mechanical ventilation after prolonged use.

Tvardi Therapeutics is developing oral small molecule therapies that target STAT3 to treat fibrosis-driven diseases, including liver cancer and idiopathic pulmonary fibrosis (IPF). The company addresses the significant unmet medical need for effective treatments in these conditions, which currently lack adequate therapeutic options.

Provides an AI-driven ECG analysis tool that non-invasively maps atrial fibrillation and six other arrhythmias, delivering detailed four-chamber cardiac insights. This technology improves cardiac ablation outcomes and procedural efficiency by integrating seamlessly into existing workflows, addressing the high mortality and morbidity associated with untreated arrhythmias. FDA-cleared for seven arrhythmias and two pacing types, it transforms standard ECGs into actionable clinical data.